(Q30397620)

English

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial (English)

1 reference

Europe PubMed Central

21 June 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

Sally Batham

3

0 references

Jonathan Nguyen Van-Tam

object named as

Jonathan S Nguyen-Van-Tam

8

0 references

Keith R. Abrams

object named as

Keith R Abrams

2

0 references

object named as

Robert C Read

9

0 references

6

object named as

Wei Shen Lim

1 reference

Europe PubMed Central

21 June 2017

11

object named as

Maria Zambon

1 reference

Europe PubMed Central

21 June 2017

author name string

Karl G Nicholson

1

1 reference

Europe PubMed Central

21 June 2017

Tristan W Clark

4

1 reference

Europe PubMed Central

21 June 2017

Katja Hoschler

5

1 reference

Europe PubMed Central

21 June 2017

Marie-Jo Medina

7

1 reference

Europe PubMed Central

21 June 2017

Fiona C Warren

10

1 reference

Europe PubMed Central

21 June 2017

publication date

16 December 2010

1 reference

Europe PubMed Central

21 June 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

21 June 2017

11

1 reference

Europe PubMed Central

21 June 2017

91-101

1 reference

Europe PubMed Central

21 June 2017

2

1 reference

Europe PubMed Central

21 June 2017

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Summary of Clinical Trials of Influenza Virus Vaccines in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel influenza A (H1N1) vaccine in various age groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Reproducibility of serologic assays for influenza virus A (H5N1).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular analysis of an outbreak of influenza in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK c

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970296-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(10)70296-6

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30397620&oldid=1632085591"